Experts Say GLP-1 Drugs May Help Women With PMOS Manage Weight

By: Women Entrepreneurs Review Team | Monday, 2 November 2026

Weight-loss injections may help certain women with Polyendocrine Metabolic Ovarian Syndrome (PMOS), previously known as PCOS, control excess weight and associated metabolic concerns. However, medical experts emphasize that these medications do not cure the hormonal condition and must only be used under proper medical supervision.

As glucagon-like peptide-1 (GLP-1) receptor agonists become increasingly popular for weight management, specialists recommend personalized treatment approaches for women with PMOS. Treatment decisions should consider individual symptoms, body weight, metabolic health and reproductive goals.

Dr Hrishikesh Pai, Gynecologist and IVF Specialist and Medical Director of Bloom IVF Group, cautioned against treating weight-loss injections as a universal solution for PMOS. The condition can involve irregular menstrual cycles, excessive hair growth, acne and ovulation difficulties, requiring comprehensive and individualized medical care.

Key Highlights:

• GLP-1 weight-loss injections may help eligible women with PMOS manage excess weight but do not cure the condition
• Experts stress personalized treatment, medical supervision and long-term lifestyle changes
• Women planning pregnancy should consult doctors about medication risks and discontinuation timelines

PMOS is a complex hormonal and metabolic condition, and excess weight is only one part of the picture. While weight reduction may improve metabolic health and menstrual regularity in some women, it does not mean the underlying condition has been cured.

"Treatment must address the woman's specific symptoms and long-term health needs rather than focus exclusively on the number on the weighing scale," Dr Hrishikesh said.

Glucagon-like peptide (GLP-1) drugs alter appetite, fullness and glucose levels. They can be prescribed to eligible people to treat type 2 diabetes or weight management, depending on the drug. But PMOS is not a proven independent indicator.

The 2023 International evidence-based guideline for PCOS recommends anti-obesity medications, such as semaglutide and liraglutide, should be considered in adults with PCOS and elevated body weight in line with general guidelines for obesity management in addition to lifestyle changes.

According to the 2023 international evidence-based guideline, anti-obesity medications, such as semaglutide and liraglutide, can be reviewed for adults that have PCOS and elevated BMI, based on general obesity-management guidelines, along with lifestyle modifications.

Such medications should be administered after evaluating body weight, blood sugar levels, insulin resistance and other risk factors, said Dr Kunal Gupta, endocrinologist and consultant endocrinologist at SPARSH Hospital, Infantry Road in Bangalore.

"Not every woman with PMOS needs a weight-loss drug, and having the diagnosis alone is not a reason to start injections. Doctors need to establish whether the patient meets the criteria for pharmacological weight management and discuss the expected benefits, possible adverse effects and alternatives. These medicines should complement, rather than replace, appropriate nutrition, physical activity and follow-up," Dr Kunal said.

He also cautioned that the benefits may not persist after the treatment is discontinued, particularly if sustainable lifestyle changes and long-term weight-management strategies are not in place. Dr Gupta said weight regain can occur after stopping GLP-1 medicines as the appetite-suppressing effects diminish.

"A doctor should plan how weight and metabolic health will be monitored if treatment is stopped, instead of allowing patients to discontinue or restart the drug on their own," he said.

Dr Nehal Dhaduk, Consultant Gynaecology, PB Health, Gurugram, said women should be counseled about the possibility of weight regain before starting treatment.

"Patients should understand that these medicines are not a quick fix for PMOS. Weight gain can occur after discontinuation as the appetite-suppressing effects diminish, although the extent varies between individuals. Women should have a long-term management plan and remain in touch with their doctors rather than stop or restart injections on their own," Dr Nehal said.

Common side-effects include nausea, vomiting, diarrhoea, constipation and abdominal discomfort. Some patients may also develop more serious complications, including gallbladder problems or pancreatitis, Dr Dhaduk said.

Medical supervision is necessary to assess risks, select the appropriate medicine and monitor treatment, she added.

Gynecologist Dr Megha Mittal, Senior Consultant, Obstetrics and Gynecology, Apollo Spectra Hospital, Delhi, added that another important point is pregnancy planning because the chances of conceiving have a possibility to improve if there is a metabolic improvement and ovulation occurs in such women that suffer from PMOS.

"Women planning pregnancy must discuss these medicines with their doctors before starting treatment. These drugs should not be used for weight loss during pregnancy, and the recommended interval between stopping treatment and attempting conception depends on the medicine," Dr Megha said.

"For instance, semaglutide should be discontinued at least two months before a planned pregnancy. Women should also discuss contraception and preconception care with their gynecologist," she said.

Dr Mittal underlined that PMOS management should address menstrual health, fertility goals, mental well-being and metabolic risks, including type 2 diabetes.